sözaltı news Finance
Finance
EN AZ
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

marketwatch.com 13.10.2026 17:17 29 views
The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.
Similar stories 1 outlet
Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says arstechnica.com 14.10.2026
Related stories
Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter
Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter
marketwatch.com · 03.11
 Apple’s iPhone business is booming. Here’s why the stock is falling anyway.
Apple’s iPhone business is booming. Here’s why the stock is falling anyway.
marketwatch.com · 03.11
 From scooters to shampoo - the people saving hundreds from dumpster diving
From scooters to shampoo - the people saving hundreds from dumpster diving
bbc.co.uk · 03.11
 US to hold first talks with Russia and Ukraine since February
US to hold first talks with Russia and Ukraine since February
ft.com · 03.11
 Apple unsure when more foldable iPhones will be available after selling out
Apple unsure when more foldable iPhones will be available after selling out
bbc.co.uk · 03.11
 Nasdaq-100 tumbles into its third correction this year as AI worries mount
Nasdaq-100 tumbles into its third correction this year as AI worries mount
marketwatch.com · 03.11